Aerie Pharmaceuticals Inc. (AERI) filed a Form 8K – Regulation FD Disclosure – with the U.S Securities and Exchange Commission on August 10, 2016.
On or after August 10, 2016, representatives of Aerie Pharmaceuticals, Inc. (the “Company”) may present to various investors the information described in the slides attached to this report as Exhibit 99.1 hereto, which is hereby incorporated by reference into this Item 7.01.
The information in this Item 7.01 (including Exhibit 99.1) is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this Item 7.01 will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Item 7.01 is not intended to, and does not, constitute a determination or admission by the Company that this information is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/1337553/000119312516677463/d231844d8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/1337553/000119312516677463/0001193125-16-677463-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company’s financial position or the value of its shares.
Copyright (c) 2016 Dow Jones & Company, Inc.